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Abstract 
 The glutamate hypothesis is a new theory of schizophrenia which proposes that 
deficient glutamatergic transmission at the NMDA receptor underlies the positive, 
negative, and cognitive symptoms of the disorder. In addition to tracing the development 
of the glutamate hypothesis in depth, this senior project presents a study investigating the 
effects of a novel antipsychotic in zebrafish.  Zebrafish are an emerging model of several 
CNS disorders, including schizophrenia, and it has been demonstrated that NMDA-R 
antagonism induces motor hyperactivity in zebrafish adults and larvae.  Previous research 
supports an ability of typical and atypical antipsychotics to reverse these motor effects in 
zebrafish adults.  The present study investigates the motor effects of MK-801 
administration in TL zebrafish larvae (n = 208) at two dose levels, as well as the ability of 
CHPG (an agonist at the metabotropic glutamate 5 receptor) to reverse these effects.  The 
findings indicate that MK-801 decreased motor activity at a dose of 20 µM. CHPG 
increased motor activity at a dose of 360 µM, an effect that was blocked by co-
administration of 2 µM MK-801.  The relevance of these findings to the development of 
antipsychotics based on the glutamate hypothesis is discussed.          
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Introduction 
 
 This senior project will focus on a new hypothesis of schizophrenia called the 
glutamate hypothesis.  The glutamate hypothesis postulates that disruption of 
glutamatergic transmission at NMDA receptor sites underlies the positive, negative, and 
cognitive symptoms of schizophrenia.  Since the 1950s, neurological hypotheses of 
schizophrenia have focused their attention on dopaminergic systems in the brain.  The 
glutamatergic systems that are the focus of the glutamate hypothesis have a 
“downstream" effect on these dopaminergic systems, allowing the old ways of thinking to 
be incorporated into the new, and painting a compelling new picture of the neural 
mechanisms underlying schizophrenia symptomatology.  Animal models play an 
important role in development of glutamate based antipsychotic agents, and in this 
project a larval zebrafish model is used to investigate the effects of CHPG, a positive 
modulator of the metabotropic glutamate receptor type 5.  The findings of this research 
are discussed into the context of the literature surrounding novel pharmacotherapies for 
schizophrenia. 
 The first chapter will introduce the reader to schizophrenia.  Following a brief 
examination of the psychological, social, and economic burdens of the disease, the three 
main categories of symptoms (positive, negative, cognitive) will be introduced and 
examples will be provided for each. 
 The second chapter will describe how the dopamine hypothesis has attempted to 
account for schizophrenic symptoms.  Starting with the first use of a dopamine antagonist 
for antipsychotic treatment, the origins of the dopamine hypothesis will be explained 
alongside early evidence for the involvement of dopaminergic transmission in 
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schizophrenia.  The chapter will explain the mechanisms of action of D2 antagonists and 
clozapine (an atypical antipsychotic), and will list the side effects of these drugs which 
have contributed in part to the continual development of novel antipsychotic agents.  
Perhaps most importantly, the chapter will summarize the dopamine hypothesis’ 
theoretical gaps surrounding the negative and cognitive symptoms, as well as the unmet 
therapeutic needs left by the typical and atypical antipsychotics. 
 The third chapter will begin with a history of the glutamate hypothesis, which 
stems from the findings of neurological studies on dissociative anaesthetics such as PCP 
and ketamine, drugs that block the NMDA glutamate receptor.  This will lead into a 
description of the proposed model of glutamate disruptions in pathways that act on the 
dopamine pathways described in the previous chapter.  The chapter will end with an 
overview of the metabotropic glutamate receptors, with a specific focus on the 
metabotropic glutamate type 5 receptor and agents that modulate activity at this receptor.   
 The fourth chapter will review recent studies on zebrafish that support the 
glutamate hypothesis.  The findings of these studies will in part provide a rationale for the 
study conducted in this senior project.  The main component of this chapter is an 
empirical study testing the effects two different dose levels of MK-801, a non-selective 
NMDA receptor antagonist, and CHPG, an agonist at the metabotropic glutamate 
receptor type 5, on motor activity in larval zebrafish whether administered individually or 
together.   
 The final chapter will summarize the findings of the zebrafish study in the context 
of the glutamate hypothesis and will conclude with suggestions for future research. 
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Chapter I: Schizophrenia and its Symptoms 
 
 Schizophrenia is the most prevalent and best known, as well as the most persistent 
and debilitating, of all the psychotic disorders.  It is a chronic illness that ranks among the 
top ten causes of disability in developing countries (WHO 2002).  The world wide 
prevalence of schizophrenia has been reported at 1-1.1%. In the United States, there are 
over 300,000 acute schizophrenic episodes annually.  It is an illness that causes great 
psychological and emotional suffering to those who have it. Rates of depression and 
social isolation are high among those with schizophrenia.  The mortality rate of people 
with schizophrenia is eight times as high as that of the general population, due in part to 
the fact that between 25-50% of people with schizophrenia will attempt suicide.  Recent 
meta-analyses have concluded that 4-4.9% of schizophrenics commit suicide (Palmer et. 
al. 2005; Inskip et. al. 1998), compared to a 2-9% suicide rate among people with 
depression (Mayo Clinic 2000).  The World Health Organization reports an average 
reduced life expectancy of 10 years (Samnaliev & Clark 2008).  The illness also 
represents a great burden to society as a whole, with 15% of people with schizophrenia 
residing for long periods in state or county mental health facilities (Javitt & Coyle 2004).  
Patients with schizophrenia occupy about 25-30% of all beds in hospitals, as well as 
accounting for 40% of all long term care days in the U.S (Chavez-Noriega et. al. 2002). 
According to Javett and Coyle (2004) around 15% of people with schizophrenia end up 
incarcerated for petty crimes and vagrancy, 60% live in poverty, and 5% are homeless.  
The estimated annual costs for treatment are $20-35 billion in the U.S. alone, an amount 
that jumps to over $46 billion when the cost of lost productivity is factored in.  These 
statistics hint at the importance of finding effective ways to manage symptoms and care 
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for people with this disease.  Although a pharmacological approach is the most widely 
accepted and effective form of treatment for both acute and chronic schizophrenia, 
antipsychotics alleviate all symptoms in only about 20% of patients (Javitt & Coyle 
2004), while 30% of patients are completely unresponsive to typical antipsychotic 
treatment (Chavez-Noriega et. al. 2002).  Furthermore, even among those who do 
respond to treatment with antipsychotic drugs, a large number discontinue their 
medication due to the unpleasant side effects.   
 According to the DSM-IV-TR: “The essential features of Schizophrenia are a 
mixture of characteristic signs and symptoms (both positive and negative) that have been 
present for a significant portion of time during a 1-month period (or for a shorter time if 
successfully treated), with some signs of the disorder persisting for at least 6 months” 
(American Psychiatric Association, 2000, p. 298).  The terms “positive” and “negative” 
respectively refer to whether a particular symptom is problematic because of the presence 
of a maladaptive behavior or cognitive pattern, or because of the absence of a usually 
adaptive behavior or pattern of cognition.  Positive symptoms represent distortions and 
exaggerations of normal cognitive functions, and negative symptoms represent a 
diminution or loss of normal functions.  According to the DSM-IV-TR, positive 
symptoms include distortions in thought (delusions), distortions in perception 
(hallucination), disorganized language and speech, and disorganized self-monitoring 
behavior;  negative symptoms include affective flattening, alogia (poverty of speech), 
anhedonia (lack of pleasure), and avolition.  In addition to the positive and negative 
symptoms, people with schizophrenia also suffer from cognitive symptoms, which can 
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include impaired attention, impaired informational processing, problems with serial 
learning, and problems with executive functioning (Stahl 2002). 
 Positive symptoms are further divided into two dimensions: psychotic and 
disorganized.  Psychotic symptoms include delusions and hallucinations while 
disorganized symptoms includes abnormalities in the form and structure of thought, 
speech, and behavior. 
 Delusional beliefs have four key features: they are objectively false, idiosyncratic, 
illogical, and stubbornly maintained.  Delusions of influence consist of the patient 
believing they are being controlled by an outside force (delusions of control), that alien 
thoughts have been “inserted” into their mind against their will (thought insertion), or that 
an outside force has taken away their thoughts (thought withdrawal).  Delusions of self-
significance consist of gross distortions of self-importance, the belief that environmental 
sources are continually referencing the patient, or the assumption of illogical and 
exaggerated guilt or responsibility.   
 The hallucinations present in schizophrenia are most often auditory (80%), 
although they can be visual, olfactory, gustatory, or tactile (Stahl 2002).  These 
hallucinations are distortions or disruptions of normal perceptual functioning, and can be 
very distressing for the schizophrenic person.  The most common hallucinations are 
auditory hallucinations in the form of spoken voices.  A particularly problematic subtype 
of auditory hallucinations is called “command hallucinations”, in which voices tell an 
individual to hurt his/herself or others (Javitt & Coyle 2004). 
 While hallucinations and delusions represent the psychotic dimension of positive 
symptoms, the speech/thought disorder in schizophrenia, as well as agitation, represents 
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the disorganized dimension.  This symptom dimension is expressed as exaggerations or 
distortions in speech and thought.  In diagnostic interviews, people with schizophrenia 
may give answers that are irrelevant or incoherent, and have trouble maintaining a 
logical, cohesive flow to their speech; they may jump from one subject to another with no 
transitions, or speak in loose associations; they may use neologisms (newly created words 
or idioms that do not make any sense); or they may repeat certain words and phrases over 
and over (Stahl 2002).  Agitation, another symptom of the disorganized dimension, may 
be expressed as stereotyped behavior or diminished impulse control, and can also be 
expressed in speech as “word salad” (Javitt & Coyle 2004).  Additionally, motor 
symptoms appear in at least 50% of psychotic patients (Seibt et. al. 2010). 
 The negative symptoms of schizophrenia are characterized by a reduction in 
normal functioning.  Affective flattening or “blunted affect”, a commonly observed 
negative symptom, consists of restrictions in the range and intensity of the person’s 
emotional expression, and is;  alogia is a restriction in the fluency and productivity of 
thought and speech; avolition is a restriction in the initiation of goal-directed behavior, 
speech, or movement; anhedonia is a restriction in the ability to feel pleasure (Stahl 
2002).  Another negative symptom is “autism” (not to be confused with the disorder on 
the autism spectrum), which refers to a loss of interest in other people or a one’s own 
surroundings (Javitt & Coyle 2002).   
 Individuals with schizophrenia also display cognitive symptoms, deficits or 
disruptions in normal cognitive functioning.  While individuals with schizophrenia are 
likely to exhibit impairment on a wide assortment of neuropsychological tasks, recent 
findings have specifically highlighted deficits in selective attention, executive function, 
ASSESSMENT OF A NOVEL ANTIPSYCHOTIC IN ZEBRAFISH 11 
motor and tactile dexterity, special abilities, affect recognition, intellectual ability, 
language functions, and memory (Heinrichs & Zakzanis 1998). For instance, a 
characteristic cognitive symptom of schizophrenia is prepulse inhibition (PPI) 
impairment. PPI is the ability to adapt to an loud auditory stimulus that is preceded by a 
warning tone.  People with schizophrenia have been found to have deficiencies in their 
PPI.  It is believed to reflect a defect in attentional “filtering” of nonnovel stimuli (Goff 
& Coyle 2001).  Additionally, individuals with schizophrenia tend to show impairment 
on tasks that test working memory, such as spatial delayed-response tasks, the Wisconsin 
Card Sorting Task, the Stroop test, and the Tower of London task (Goldman-Rakic 1994).  
 The severity of an individual’s cognitive symptoms has been shown to be the best 
predictor of long-term outcome (Chavez-Noriega 2002).  This could be because the 
severity of cognitive symptoms may represent the severity of the individual’s illness as a 
whole, or because cognitive symptoms have functional consequences that affect long-
term outcome.  For instance, a literature review conducted by Green (1996) found that 
performance on secondary verbal memory (the ability to recall lists of words or stories 
after a time delay) and card sorting cognitive tasks predicted community functioning 
outcome in people with schizophrenia; secondary verbal memory and vigilance (the 
ability to discriminate targets from non-targets in cognitive response tasks) predicted 
social problem-solving ability; immediate verbal memory (the ability to repeat back a 
series of digits), secondary verbal memory, and  vigilance predicted capacity for skill 
acquisition in psychosocial rehabilitation programs.  A recent longitudinal study by 
Shrivasatva et. al. (2011) showed that regardless of improvement on the Clinical Global 
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Rating scale, individuals with schizophrenia still displayed deterioration of visuo-motor 
integration, working memory, and executive functioning over a period of ten years. 
 There is no question that if cognitive deficits are present, an individual can be 
expected to experience difficulties in other areas of their life such as social and emotional 
functioning.  However, despite the evidence that cognitive symptoms are a severely 
debilitating dimension of schizophrenia, current pharmacological treatments mostly offer 
relief from only the positive symptoms of the disease, with minimal or no effect on the 
negative and cognitive symptoms (Lindsley et. al. 2006).  Therefore, relief from negative 
and cognitive symptoms represents a substantial unmet medical need. 
 Sine the 1950s, the gold standard for treatment of schizophrenia has been 
treatment with dopamine antagonists, which are generally efficacious for ameliorating 
positive symptoms while ineffective for treating negative and cognitive symptoms.  First 
generation antipsychotics still represent a large percentage of the agents used, though 
recently atypical antipsychotic treatment and development has become more prominent.  
Atypical antipsychotics are compounds that have antagonist activity at serotonin (5HT) 
type 2A receptors in addition to antagonist activity at dopamine type 2 receptors.  They 
have been shown to have less side effects than first generation antipsychotics – as well as 
encouraging (albeit inconsistent) efficacy for a broader variety of symptoms than first 
generation antipsychotics – but there is a lack of comprehensive understanding of why 
they work when they do. 
 While researchers have continued to attempt to illuminate the mechanisms of 
action of the atypicals antipsychotics, new psychotomimetic paradigms and the ongoing 
need to find therapeutic agents with efficacy for both negative and cognitive symptoms 
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has shifted the focus of much schizophrenia research onto the glutamate systems.  
Glutamate-based drug therapies may be a novel way to treat negative and cognitive 
symptoms alongside positive symptoms.  In order to understand how this new class of 
drug will work to affect changes in the brain and differ from first and second generation 
antipsychotics, it is important to review the current theories of schizophrenia.  The next 
chapter will briefly explain the theoretical underpinnings that have historically guided 
antipsychotic drug development, known as the dopamine hypothesis, as well as the 
mechanisms by which antipsychotic drugs work. 
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Chapter II: The Dopamine Hypothesis and Antipsychotics 
 For the last 60 years, pharmacotherapies and neurological models of 
schizophrenia have focused heavily on one neurotransmitter: dopamine.  Dopamine is a 
member of the catecholamine family and plays an important role in behavior and 
cognition, voluntary movement, punishment and reward, inhibition of prolaction 
production, sleep, mood, attention, working memory, and learning.  The dopamine 
hypothesis states that dopamine dysregulation in the central nervous system results in the 
symptoms of schizophrenia.  The origins of this theory lie in the history of the 
development of antipsychotic drugs.  In 1950 a Naval surgeon named Henry Laborit 
noted that the secondary effects of promethazine, a drug intended for use as a surgical 
sedative, included drowsiness, indifference to pain, and general euphoria.  Laborit began 
to consider other possible applications for the drug, while also encouraging Laboratoires 
Rhône-Poulenc to synthesize a similar compound with increased psychological effects. 
Paul Charpentier was the chemist who then designed chlorpromazine (Thorazine) in 
1951, which was distributed to physicians and psychiatrists for use as an antipsychotic.  
By 1954 chlorpromazine was being used in the United States to treat schizophrenia, and 
as its therapeutic use grew more popular, research was targeted at discovering its 
neurological mechanism(s) of action. 
 By the early 1960s, empirical findings had shown that the first generation of 
antipsychotics (commonly referred to as typical antipsychotics or neuroleptics) acted as 
antagonists on dopamine type D2 receptors, binding to these receptor sites and decreasing 
dopamine release. Furthermore, side effects resembling Parkonson’s disease were 
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observed early on in clinical trials of antipsychotics, and these observations contributed 
to the understanding that typical antipsychotics acted on dopamine neurons.  Research 
had already established Parkinson’s disease as a result of deficient dopamine in the brain, 
especially in the nigrostriatal dopamine pathway (Mueser & Jeste 2008; Lauelle et. al. 
2005; Stahl 2002).  Around the same time, Arvid Carlsson demonstrated that 
amphetamines administered to healthy subjects induce hallucinations and delusions 
(analogous to the positive symptoms of schizophrenia) via indirect agonist activity at 
dopamine D2 receptors.  Carlsson’s research was inspired by earlier findings from studies 
of symptoms present in patients hospitalized for amphetamine psychosis: the patients 
frequently experienced auditory hallucinations much like those typically reported in 
schizophrenia – vague noises, voices that the patients occasionally conversed with – as 
well as visual hallucinations that resembled those reported by schizophrenic individuals 
during acute psychotic episodes (Snyder et. al. 1974). The dopamine hypothesis arose out 
of all of these early clinical observations. The current rationale for this hypothesis 
implicates dopamine as a causative neurotransmitter in schizophrenia based on the 
combined evidence that: 1) all clinically relevant antipsychotic agents display significant 
antagonistic activity at the dopamine D2 receptor; 2) indirect dopamine agonists, such as 
amphetamine and cocaine, have been shown to induce positive psychotic symptoms both 
human and animal subjects; and 3) many of the patients treated with first generation 
antipsychotics displayed Parkinsonian side effects, pointing towards dopamine 
antagonism as the mechanism of action by which these drugs acted on the brain. 
 Informed by pharmacological discoveries, the dopamine hypothesis implicates 
hyperactivity of dopamine in the mesolimbic dopamine pathway as the cause of the 
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positive symptoms of the disease.  The dopamine neurons of this pathway have cell 
bodies located in the ventral tegmental area; dopamine is carried to the nucleus 
accumbens via the amygdala and hypothalamus.  Hyperactivity of dopamine neurons in 
this pathway is thought to be responsible for the hallucinations and delusions present in 
schizophrenia (Stahl 2003).  
Figure 1. Dopamine hyperactivity in mesolimbic pathway results in overactive post-
synaptic dopamine neurons. 
  
 Negative and cognitive symptoms are accounted for via a different dopamine 
pathway.  The mesocortical dopamine pathway is comprised of dopamine neurons whose 
cell bodies are, like those of the mesolimbic pathway, located in the ventral tegmental 
area.  However, unlike those neurons of the mesolimbic pathway, these neurons project 
dopamine to areas of the cerebral cortex, such as the dorsolateral prefrontal cortex, as 
well as many structures in the limbic system (Stahl 2002).  According to the dopamine 
hypothesis, hypoactivity of these neurons is responsible for the negative and cognitive 
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symptoms seen in schizophrenia.  While there has been considerable progress in the 
development of pharmacological agents to treat positive symptoms, biological treatments 
for the negative and cognitive symptoms remain unsatisfactory.      
 All first generation antipsychotics (also known as typical antipsychotics, or 
neuroleptics) inhibit dopamine 2 receptors.  This ability to block D2 receptors is 
responsible for their clinical efficacy.  By inhibiting D2 receptors in the mesolimbic 
dopamine pathway, neuroleptics can reduce hallucinations and delusions in people with 
schizophrenia (Stahl 2002).  The efficacy of a neuroleptic in reducing positive symptoms 
is correlated with the compound’s affinity for the D2 receptor (Snyder et. al. 1974; Stahl 
2002).  
 
Figure 2. D2 Antagonists inhibit post-synaptic hyperactivity of dopamine neurons. 
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 While this method of drug treatment does provide reliable relief from positive 
symptoms in a majority of patients (roughly 70%), there are several drawbacks to 
neuroleptic treatment (Chavez-Noriega et. al. 2002).  Antipsychotic drugs are delivered to 
the brain through oral ingestion, and therefore these compounds bind non-selectively to 
every D2 receptor in the brain, leading to decreased activity in both the mesolimbic 
pathway and mesocortical pathway.  The result is that, while positive symptoms are 
alleviated due to antagonist activity in the mesolimbic pathway, negative and cognitive 
symptoms may be worsened due to antagonism in the mesocortical pathway – a condition 
referred to as the neuroleptic-induced deficit syndrome (Stahl 2002).  Furthermore, many 
side effects are a result of the fact that in addition to the two pathways already mentioned, 
two other relevant dopamine pathways in the brain are blocked by neuroleptics – the 
nigrostriatal dopamine pathway, and the tuberoinfundibular dopamine pathway.   
 The nigrostriatal pathway is part of the extrapyramidal nervous system, 
responsible for controlling motor movements.  In Parkinson’s disease, deterioration of the 
nigrostriatal pathway is responsible for symptoms such as rigidity, akinesia (loss of 
control of voluntary movement), bradykinesia (impaired ability to adjust one’s body 
position), and tremor.  By blocking D2 receptors in this pathway, typical antipsychotics 
may cause drug-induced parkinsonism, as well as akathisia (a syndrome characterized by 
unpleasant “inner restlessness” that may manifest as an inability to sit still or remain 
motionless) and dystonia (characterized by twisting movements and abnormal postures 
due to sustained muscle contractions).  Side effects on movement resulting from reduced 
dopamine in the nigrostriatal pathway are commonly referred to as extrapyramidal side 
effects, or EPS.  Chronic blockade of D2 receptors in the nigrostriatal pathway may 
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produce a hyperkinetic movement disorder called tardive dyskinesia, characterized by 
constant chewing, tongue protrusions, facial grimacing, and jerky or choreiform limb 
movements (Stahl 2002).  Annual incidence of neuroleptic-induced tardive dyskinesia is 
5% (Stahl 2002), and in many cases it is an irreversible condition.   
 In addition to the side effects caused by blockade of the nigrostriatal pathway, 
patients may experience side effects caused by blockade of the tuberoinfundibular 
pathway.  When D2 neurons in this pathway are blocked plasma prolactin levels increase, 
which may result in a condition called hyperprolactimea.  This condition is associated 
with breast secretions, irregular menstrual periods, and demineralization of bones in 
women.  Further side effects may include sexual dysfunction and weight gain due to 
elevated prolactin levels (Stahl 2002). 
 Clearly there are many risks inherent in conventional antipsychotic treatment 
despite the benefits of alleviated positive symptoms.  Side effects are associated with 
discontinuation of medical treatment by patients at a rate of 10% per month, resulting in a 
50% relapse rate by 6 months after medication has been discontinued (Stahl 2002).  
Furthermore, 30% of individuals with schizophrenia do not respond to typical 
antipsychotics (Chavez-Noriega et. al. 2002; Sajatovic et. al. 2008).  The development of 
atypical antipsychotics was intended to remedy this situation.  The goal in the 
development of the atypicals has been to decrease the prevalence of unpleasant side 
effects as well as increase clinical efficacy for more symptoms in a larger portion of the 
patient population.    The improved efficacy and reduced extrapyramidal side effects of 
treatment with clozapine, the prototype drug of the atypical class, has led to the 
development of atypicals such as risperidone, olanzapine, quetiapine, ziprasidone, 
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aripiprazole, and paliperidone.  According to a European review (Seshamini 2002) 
treatment with clozapine improves patient symptoms and quality of life, as well as 
reduces the number of hospitalizations in individuals with schizophrenia. Clozapine has 
antagonist activity at dopamine type 2 receptors much like haloperidol.  Additionally, 
clozapine blocks seretonin type 2A (5HT-2A) receptors.  Serotonin and dopamine 
interact in the nigrostriatal dopamine pathway of the brain, the pathway responsible for 
the Parkinsonian side effects that can be caused by treatment with typical antipsychotics 
such as haloperidol.  In this pathway, serotonin acts as a brake by inhibiting dopamine 
neurons.  By blocking 5HT-2A receptors here, 5HT-2A antagonism can reverse the 
dopamine type 2 antagonism resulting from blockade of dopamine receptors, leading to 
fewer or no extrapyramidal symptoms than those that result from the dopamine 
antagonism of typical antipsychotics (Stahl 2002). 
 However, while atypical antipsychotics are not associated with the extrapyramidal 
side effects that characterize neuroleptic treatment, the atypicals have their own side 
effect profile which can contribute to the problem of treatment discontinuation in the 
same way that typical antipsychotic side effects have. When compared to haloperidol, 
clozapine is associated more with hypersalivation, temperature increase, and drowsiness, 
but fewer motor side effects and less dry mouth (Sajatovic et. al. 2008).  Clozapine side 
effects can include agranulocytosis (dangerous lowering of white blood cell count leading 
to increased risk of infections), granulocytopenia (another lowering of white blood cell 
count), sedation, seizures, fevers (100-103˚F), neuroleptic malignant syndrome (a life-
threatening neurological disorder characterized by muscle rigidity, fever, autonomic 
instability, and delerium), development of obsessive-compulsive symptoms, tachycardia 
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(potentially dangerous increase of resting heart rate), orthostatic hypotension (low blood 
pressure), prolongation of QTc interval (which may lead to palpitations, fainting, or 
sudden death), deep vein thrombosis (blood clotting in various limbs), myocarditis 
(inflammation of the heart muscles with a 20% mortality rate), cardiomyopathy 
(deterioration of heart muscles), sialorrhea (excessive drooling), urinary retention, 
constipation, gastrointestinal obstruction, and enuresis (involuntary urination) (Sajatovic 
et. al. 2008).  In addition, McGurk et. al. (2005) suggested that the anticholinergic effects 
of clozapine may be responsible for the worsening of spatial working memory in 
individuals with schizophrenia.  Furthermore, research has failed to find consistent 
significant data supporting atypical drugs efficacy for cognitive and negative symptoms.  
On a final note, clozapine use is limited to about 5% of patients in clinical settings due to 
its adverse side effect profile, need for regular laboratory monitoring, and cost (Satajovic 
et. al. 2008). 
 The dopamine hypothesis has laid the foundations for an understanding of the 
neural mechanisms underlying many symptoms of schizophrenia, as well as leading to 
the development of antipsychotic agents.  However, there are still unanswered questions 
about the neural mechanisms of negative and cognitive symptoms, and current 
antipsychotic treatments have been inconsistent in ameliorating these symptoms.  
Additionally, the adverse side effect profiles of antipsychotics demonstrate that the 
current state of pharmacotherapies for schizophrenia is one that can be improved upon.  
In recent years a new hypothesis of schizophrenia, the glutamate hypothesis, has led to 
the possibility of the development of antipsychotic treatments which are efficacious for a 
broader range of symptoms, and which may also avoid the side effects of current 
ASSESSMENT OF A NOVEL ANTIPSYCHOTIC IN ZEBRAFISH 22 
antipsychotic administration.  The next chapter will review the glutamate hypothesis, as 
well as antipsychotic agents that have been developed based on this new direction in 
schizophrenia research. 
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Chapter III: The NMDA-R Hypothesis of Schizophrenia 
 
 In the last twenty years, researchers investigating the etiology of schizophrenia 
have shifted their focus from dopamine systems to “upstream” glutamate systems that 
have modulating effects on the relevant dopamine pathways implicated in schizophrenia.  
Glutamate is the primary excitatory neurotransmitter in the brain, which means it 
activates many neurons.  It is fairly ubiquitous (60% of neurons contain glutamate, and 
almost all neurons have some type of glutamate receptor), and plays a role in prenatal and 
childhood development, learning, and memory (Harvard Mental Health Letter 2009).  
Glutamate also has a modulating effect on the dopamine pathways implicated in the 
dopamine hypothesis.  By looking at glutamate’s role in schizophrenia, researchers have 
begun to formulate a model of the disease which incorporates the whole of the dopamine 
hypothesis while also accounting for aspects of schizophrenia which the dopamine 
hypothesis has been unable to explain.   
 The glutamate hypothesis comes out of research with the dissociative anesthetics 
PCP and ketamine.  According to Javitt & Coyle (2004) studies first drew parallels 
between the effects of PCP and the symptoms of schizophrenia as early as the 1960s.  
PCP acts as a nonselective antagonist at the NMDA glutamate receptor, binding to a site 
within the ion channel and blocking the influx of cations that leads to an action potential 
(Goff & Coyle 2001).  The NMDA receptor is a ligand- and voltage-gated 
calcium/sodium channel that is believed to play a role in both learning and memory 
(Sison & Gerlai 2011; Javitt 1987), .  Ketamine has the same mechanism of action at the 
NMDA receptor, with a lower affinity than PCP.  As psychotomimetics, there is 
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compelling evidence that these NMDA receptor antagonists can produce a psychotic state 
more closely resembling the symptom profile of schizophrenia than dopamine agonists 
such as amphetamine or methylphenidate.  While dopamine agonists only induce effects 
similar to the positive symptoms of the disease, PCP and ketamine can give rise to a state 
that resembles the full range of positive and negative symptoms in schizophrenia 
including hallucinations, thought disorder, specific cognitive impairment, emotional 
withdrawal, and apathy (Javitt 1987; Stone 2009).  PCP can produce a syndrome in 
normal individuals that closely resembles schizophrenia and exacerbates symptoms in 
patients with chronic schizophrenia (Luby et. al. 1959).  Ketamine can produce positive 
symptoms in the form of suspiciousness, disorganization, and auditory and visual 
hallucinations; negative symptoms in the form of blunted affect, withdrawal, and 
psychomotor retardation; and cognitive symptoms including impaired performance on the 
Wisconsin Card Sorting Test (which is used to test a number of cognitive abilities 
including attention, memory, visual processing, and other executive functions) and on 
verbal declarative memory, delayed word recall, and impairment on verbal fluency tests 
(Goff & Coyle 2001).  In fact, both ketamine and PCP mimic schizophrenia so well that 
patients treated with either of these drugs cannot be readily distinguished from 
individuals with schizophrenia in clinical settings (Javitt & Zukin 1991). 
 Observations on the psychomimetic effects of these NMDA receptor antagonists 
have led to the development of a NMDA-R hypothesis of schizophrenia, referred to as 
the glutamate hypothesis.  The glutamate hypothesis attributes the symptoms of 
schizophrenia to hypofunctional NMDA receptors that have a downstream effect on the 
two major dopamine pathways implicated in the dopamine hypothesis.  There is an 
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important descending glutamatergic pathway which projects from cortical pyramidal 
neurons to dopamine neurons in the ventral tegmental area (VTA), which normally acts 
as a brake on the mesolimbic dopamine pathway by exciting γ-aminobutyric acid 
(GABA) interneurons in the VTA to inhibit dopamine release from the mesolimbic 
pathway.  Hypoactivity at NMDA receptors in schizophrenia would lead to a decrease in 
activation of GABA interneurons, thereby leading to hyperactivity of the mesolimbic 
pathway – responsible for the positive symptoms of the disease (hallucinations, 
delusions, thought disorder, agitation). 
Figure 3. NMDAR hypofunction leads to positive symptoms (Stahl 2002).   
 
 
 
 
 
 
 
 
 
 
 
Another important glutamate pathway extends from the cortical regions of the brain 
caudally to the brainstem, and the neurons of this pathway normally have an excitatory 
effect on the dopamine neurons of the mesocortical dopamine pathway.  Hypoactivity at 
QuickTime™ and a
 decompressor
are needed to see this picture.
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NMDA receptors in schizophrenia would lead to decreased dopamine activity in the 
mesocortical pathway – thereby accounting for the negative symptoms (blunted affect, 
withdrawal, avolition) and cognitive symptoms (working memory impairment, executive 
functioning deficits) of the disorder (Stahl 2007). 
Figure 4. NMDAR hypofunction leads to negative and cognitive symptoms (Stahl 
2002). 
 
 
 
 
 
   
  
 
  
 
 Several neurological findings are consistent with the glutamate hypothesis: 
studies have shown significantly lower levels of glutamate in the cerebrospinal fluid and 
postmortem brain tissue of individuals with schizophrenia than in controls; cerebrospinal 
fluid glutamate levels have been shown to be inversely correlated to the severity of 
positive symptoms in unmedicated individuals with schizophrenia; levels of kyuneric 
acid (an endogenous ionotropic glutamate antagonist with activity at the glycine site of 
NMDA receptors) have been found to be elevated in the cerebrospinal fluid and cortical 
QuickTime™ and a
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are needed to see this picture.
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tissue of schizophrenics compared to controls; and a number of studies have reported 
alterations in gene and receptor expression in cortical, hippocampal, and thalamic regions 
for several glutamate receptors including the NMDA receptors (Chavez-Noriega et. al. 
2002). 
 Genetic findings from animal models also support the glutamate hypothesis.  
Several studies have shown that decreased expression of the NR1 subunit, required in 
mice for normal NMDA receptor function, leads to a range of phenotypic symptoms 
analogous to schizophrenia such as increased locomotor activity, stereotypy and deficits 
in social and sexual interactions, which can be ameliorated by treatment with haloperidol 
and clozapine (Chavez-Noriega et. al. 2002); furthermore, symptoms such as disruption 
of pre-pulse inhibition, spatial working memory, and GABA interneuron expression are 
more likely to occur if NR1 deletion occurs during early developmental windows – 
consistent with the neuro-developmental aspect of schizophrenia (Gordon 2010).  NR2 
knockout display schizophrenic-like behaviors that can be ameliorated with antipsychotic 
drug treatment, and NR1 glycine site knockout mice display impairment in LTP and 
learning (Linsley et. al. 2006).  A study using metabotropic glutamate type 5 receptor 
knockout mice demonstrated a significant reduction in the NMDA-component of synaptic 
transmission, as well as long-term potentiation, in hippocampal field CA1 and the dentate 
gyrus (Lu et. al. 1997).  Kinney et. al. (2003) were able to demonstrate that mGluR5 
knockout mice had significant deficits in PPI when compared to wild-type controls.  
 In light of the growing body of evidence in support of the glutamate hypothesis, it 
has been suggested that modulation of glutamatergic transmission be used as a novel 
pharmacotherapy for schizophrenia, and thus several compounds that have action at 
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glutamate receptors have been developed for research.  Metabotropic glutamate receptors 
(mGluRs) have emerged as promising targets for development of new ligands.  The 
relative uneven distribution in the brain of mGluRs, compared to ionotropic glutamate 
receptors (iGluRs), gives rise to the possibility that selective modulators of mGluR 
function might be used to target specific aspects of glutamatergic activity in specific 
neural circuits.  While none of these agents are currently approved for clinical use in 
humans because they are still so early in the development and research process, several 
studies have shown that modulation of glutamatergic transmission at metabotropic 
receptor sites may be able to ameliorate symptoms of schizophrenia.        
 The metabotropic glutamate receptors belong to the family C of seven 
transmembrane receptors that couple with G proteins and control to the activity of 
membrane enzymes and ion channels in the neuron (Kanuma et. al. 2010).  There are 
eight known types of mGluRs classified into groups I, II, and III according to primary 
structure, second messenger coupling, and pharmacological profile.  Group I (containing 
mGluR1 and mGluR5) and group II (containing mGluR2 and mGluR3) have both been 
identified as potential targets for novel antipsychotic agents.  
Figure 5. Classification of metabotropic glutamate receptors. 
Group Receptor Signal 
transduction 
mechanism 
Primary localization 
I mGluR1 ⇑PLC Postsynaptic; forebrain/midbrain 
I mGluR5 ⇑PLC Glia, postsynaptic; 
forebrain/midbrain 
II mGluR2 ⇓AC Pre/postsynaptic; forebrain 
II mGluR3 ⇓AC Glia, postsynaptic; forebrain 
III mGluR4 ⇓AC Pre/postsynaptic; cerebellum 
III mGluR6 ⇓AC Postsynaptic; retina 
III mGluR7 ⇓AC Pre/postsynaptic 
III mGluR8 ⇓AC Pre/postsynaptic 
AC = adenylate cyclase; PLC = phospholipase C; ⇑ indicates increase; ⇓ indicates decrease. 
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 Multiple studies have shown that activation of group I mGluRs induces 
potentiation of NMDA receptor currents in a variety of regions in the brain (Sou et. al. 
2006; Chan et. al. 2008).  In particular, activation of mGluR5 has been shown to alleviate 
locomotor, sensorigating, and cognitive deficits induced by NMDA receptor antagonists.  
Chavez-Noriega et. al. (2002) have hypothesized that activation of mGluR5 may 
normalize hypofunctional NMDAR transmission in schizophrenia, thereby representing a  
useful approach for the development of novel antipsychotic drug treatments.  There is 
supporting evidence from studies on mGluR5 antagonists, which have demonstrated that 
the mGluR5 antagonists MPEP and MTEP can worsen motor and cognitive symptoms 
induced by NMDA receptor antagonists (Krystal et. al. 2010).  According to Kanuma et. 
al. (2010) the mechanism by which activation of mGluR5 with agonist agents enhances 
NMDAR function is that it is likely that activation of mGluR5 leads to PKC 
phosphorylation of the ion channel associated with NMDA receptors, thereby resulting in 
increased NMDA receptor sensitivity and activity, and leading to an influx of calcium 
ions.  Figure 6, adapted from Kamuna et. al. (2010), is an illustration that shows this 
chain of events: glutamate binds to the mGluR5 site (drawn as a 7-transmembrane 
protein), triggering the activation of a second messenger (Gqu), leading to PKC 
phosphorylation, resulting in enhanced ionic influx.   
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Figure 6. mGluR5 activation enhances NMDAR function (Kanuma et. al. 2010)
  
  
 One particular compound that has been shown to have antipsychotic effects in 
rodent models of psychosis is the mGluR5 agonist (RS)-2-chloro-5-
hydroxyphenylglycine (CHPG).  Sou et. al. (2006) administered CHPG via 
introcerebralventricular (i.c.v.) injections to male NMRI mice that had been treated with 
either ketamine or propofol (an anaesthetic which binds to GABA subtype A neurons).  
Results indicated that CHPG decreased the duration of ketamine-induced loss of right 
reflex (LORR) at 3 dose levels (0.5, 2.5, and 5.0 nmol in a 5µL injection) in a dose 
dependant manner (5.0 nmol dose resulted in the shortest duration of LORR), but did not 
have an affect on propofol-induced LORR.  This supports the hypothesis that CHPG acts 
via modulation of NMDA receptors. 
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Figure 7.  Structure of CHPG. 
 
 In another study, Chan et. al. (2008) examined whether CHPG could reverse 
ketamine induced locomotor hyperactivity, motor incoordination, sensorimotor gating 
deficit, and learning impairment in male NMRI mice (a Swiss-bred type) and ICR 
(Inherited Cataract Rat, bred for research in neurobiology and opthamology) rats. CHPG 
reversed ketamine-induced hyperactive locomotor activity at a dose of 5 nmol delivered 
via a 5µL i.c.v. injection, but did not affect motor activity when delivered alone.  CHPG 
also improved ketamine-induced deficits in the novel object recognition test at doses of 1 
nmol and 5 nmol, respectively.  CHPG did not alter sensorimotor gating, motor 
coordination on the rotarod test, or cognitive abilities in the novel object recognition test 
when delivered alone.  This study supports the hypothesis that CHPG may be binding 
directly to the orthosteric (direct) glutamate binding site and thus increasing the intrinsic 
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effect of endogenous glutamate, leading to the enhancement of NMDA receptor function; 
at the same time, the fact that the drug had no effect on these measures when 
administered alone opposes the possibility that the reversal of ketamine-induced 
hyperactivity was due to a sedative effect, or that the reversal of cognitive deficits in the 
novel object recognition test was due to anxiolytic effects. 
 Current investigations into the ability of mGluR5 agonism to alleviate the effects 
of NMDA-R antagonism have been limited to rodent models of psychosis.  Zebrafish 
(Danio rerio) is an emerging animal model of the behavioral and cognitive disruptions 
caused by NMDA-R antagonism.  A small number of studies have demonstrated the 
ability of first and second generation antipsychotic treatment to alleviate the behavioral 
and brain changes induced by MK-801 (a non-selective NMDA-R antagonist), .  Taken 
together, these findings suggest a rationale for investigating whether or not mGluR5 
agonism can reverse the behavioral disruptions caused by administration of MK-801.  
The next chapter will include the rationale, methods, results, and discussion of a pilot 
study conducted to investigate the effects of CHPG on MK-801-induced motor symptoms 
in zebrafish larvae.
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Chapter IV: Assessing CHPG Reversal of Locomotor Effects of MK-801 in 
Zebrafish Larvae 
 
Background 
 
 Schizophrenia is a central nervous system disorder characterized by positive, 
negative, and cognitive symptoms.  All currently approved antipsychotic drugs share the 
trait of reducing dopaminergic function via antagonist or partial antagonist activity at 
dopamine type 2 receptors.  One consequence of this is that most antipsychotics are only 
effective for the treatment of the positive symptoms of the disorder (hypothesized to be a 
result of dopaminergic hyperactivity in the mesolimbic dopamine pathway), while 
negative and cognitive symptoms (hypothesized to be a result of dopaminergic 
hypoactivity in the mesocortical dopamine pathway) are alleviated inconsistently, if at 
all.  Thus, there is an incentive to develop pharmacotherapies that will be efficacious for 
the whole range of symptoms present in schizophrenia.  In the last 10 years, research has 
begun to explore modulation of glutamatergic systems as a novel approach to 
antipsychotic treatment.    
 The dopamine pathways implicated in schizophrenia are “downstream” from key 
glutamate systems in the brain.  Hypoactivity of the glutamate systems that act on the 
mesolimbic and mesocortical dopamine pathways has recently been implicated in the 
etiology of schizophrenia.  In particular, it has been suggested that dysfunction at the N-
methyl-D-aspartate (NMDA) glutamate receptor may play an important causal role in 
mediating positive, negative, and cognitive symptoms. The NMDA receptor is a ligand- 
and voltage-gated calcium/sodium cation channel that is believed to play a role in both 
learning and memory (Sison & Gerlai 2011; Javitt 1987).  Non-selective NMDA-R 
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antagonists, such as PCP and ketamine, have been found to elicit symptoms in healthy 
controls that resemble the variety of symptoms found in individuals with schizophrenia.  
Importantly, the state induced by administration of NMDA-R antagonists more 
accurately models the full range of symptoms in schizophrenia  than the psychosis 
induced by treatment with amphetamines, which increase dopaminergic activity and have 
heretofore been the most popular method of eliciting schizophrenic-like symptoms (Javitt 
1987; Stone 2009). 
 Animal models of psychosis provide opportunities for investigation into different 
aspects of schizophrenia.  The zebrafish (Danio rerio) is emerging as a model organism 
for examining the interactions of toxicology, neurodevelopment, and behavior (Padilla et. 
al. 2011).  The small (4 cm long) freshwater teleost that inhabits slow moving streams 
and small lakes of the Indian sub-continent has been argued to represent an excellent 
compromise between neurological complexity and practical simplicity (Sison & Gerlai 
2011).  The many advantages to zebrafish include low cost, ease of handling and 
maintenance, and 70-80% genetic homology to humans (Seibt et. al. 2011).  Recent 
findings suggest that zebrafish may be useful in modeling schizophrenic symptoms via 
administration of NMDA-R antagonists.  
 Dizocilpine (MK-801) is a non-selective NMDA-R antagonist that has been used 
in animal models of psychosis to elicit motor and cognitive effects.  Treatment with MK-
801 has been demonstrated to lead to a dose-dependent increase in motor activity in both 
rodent and adult and larval zebrafish models analogous to the positive symptom 
dimension in schizophrenia.  The motor effects of MK-801 are hypothesized to be 
mediated by blockade of glutamatergic transmission leading to enhanced dopaminergic 
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activity.  This mechanism of action is consistent with the mechanism of positive 
symptoms proposed by the NMDA-R hypofunction hypothesis of schizophrenia.    
 Swain et. al. (2004) used a zebrafish model to examine the effects of MK-801 on 
circling behavior, swimming activity, latency to enter (as well as preference for) an 
enriched chamber.  Consistent with findings that treatment with PCP or other NMDA 
receptor antagonists increase circling behavior in rodents, it was demonstrated that MK-
801 significantly increased circling behavior in adult zebrafish at a dose of 2 and 20 µM 
in a dose-dependent manner.  Treated fish circled “almost continuously”, whereas control 
fish displayed motor activity but rarely completed a full 360 degree circle.  Preference for 
the enriched chamber was also disrupted in fish treated with MK-801 as compared to 
controls, suggesting a possible cognitive disruption due to MK-801 treatment.     
 Seibt et. al. (2010) demonstrated that a dose of 20 µM MK-801 increased 
locomotor activity in adult zebrafish as measured by parameter line crossings, distance 
traveled, and mean speed when compared to control animals.  Co-administration of either 
9 µM haloperidol, 100 µM olanzipine, or 250 µM sulpiride was shown to reverse the 
changes in locomotor behavior induced by MK-801.  In another study, Seibt et. al. (2011) 
demonstrated that treatment with 20µ MK-801 significantly decreased Na+, K+, ATPase 
activity (which is altered in various neuropsychiatric illnesses including schizophrenia) in 
adult zebrafish.  This effect was reversed by administration of antipsychotics (haloperidol 
9 µM, olanzipine 100 µM, or sulpiride 250 µM).  Taken together, the findings of these 
two studies provide a rationale for investigating whether a novel antipsychotic agent 
could have the ability to reverse the effects of MK-801 in zebrafish. 
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 The previously cited findings are from studies on adult zebrafish, and to date there 
are very few studies on larval models that exist in the current literature.  However, in 
light of the proposed neurodevelopmental aspect of schizophrenia there may be 
knowledge to gain from investigations into zebrafish larvae as potential models of 
schizophrenic symptoms and antipsychotic effects.  A recent study provides support for 
the conservation of the motor effects of MK-801 in zebrafish larvae.  Chen et. al. (2010) 
demonstrated a dose-dependent effect of MK-801 on locomotor activity in zebrafish 
larvae 5-7 d.p.f..  MK-801 was found to significantly increase average swim speed over a 
3 hour period when administered at doses of 5, 10, 20, 50, and 100 µM.  The dose that 
elicited the maximal increase in average swim speed was 20 µM.  This study provides 
evidence that the hyperactive motor effects of MK-801 previously demonstrated in adult 
zebrafish are conserved in zebrafish larvae, contributing to a rationale for investigating 
the effects of potential antipsychotics in larval models.  The dose effects from the study 
also contribute to the rationale for using a 20 µM dose of MK-801 in the present study.  
 (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) is a novel glutamate-based 
compound which selectively binds to the metabotropic glutamate type 5 receptor 
(mGluR5).  It has previously been shown to have antipsychotic activity in rodents.  
CHPG is hypothesized to modulate glutamatergic transmission via enhancement of 
NMDA-R function.  According to Alioto & Ngai (2006) zebrafish have a genetic 
ortholog that codes for an mGlu5 receptor.  While previous studies have examined the 
effects of NMDA-R antagonism in zebrafish, to date the ability of glutamate based 
compounds to enhance NMDA-R function have never been investigated in zebrafish.  
Furthermore, despite the fact that a number of studies have demonstrated that mGluR-
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binding ligands have behavioral effects in rodents, there are very few studies that have 
assessed the degree to which these findings can be replicated in a zebrafish model.  
However, the ability of the mGluR5 antagonist MPEP (an mGluR5 antagonist which has 
been shown to increase the effects of NMDA-R antagonists) to affect the behavior of 
zebrafish in an addiction model (Tucker et. al. 2006) is sufficient reason to investigate 
whether an mGluR5 agonist can also affect larval behavior.   
 
Experiment 1 
 The purpose of this study was to assess whether treatment with the mGluR5 
agonist CHPG has any independent effects on motor activity in zebrafish larvae, as well 
as whether treatment with CHPG can reverse the locomotor hyperactivity MK-801 has 
previously been demonstrated to induce in zebrafish.  In order to achieve this, zebrafish 
larvae were observed at 5 days post fertilization following treatment with either vehicle 
(egg water), MK-801, CHPG, or a mixture of MK-801 and CHPG.  The previously cited 
studies by Swain et. al. (2004), Chen et. al. (2010), and Seibt et. al. (2011) provide 
compelling evidence to hypothesize that the zebrafish treated with MK-801 would exhibit 
increased motor activity from baseline as compared to controls.  Additionally, it was 
hypothesized that the motor activity of zebrafish treated with CHPG alone would not 
differ significantly from controls.  The rationale for this prediction was based on findings 
of Kinney et. al. (2003) and Chan et. al. (2008) which demonstrated that while CHPG 
was able to reverse NMDA-R antagonist-induced motor and cognitive symptoms in 
rodents, there was no effect on these measures when administered alone,.  This is 
consistent with the hypothesis that CHPG may be binding directly to the orthosteric 
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glutamate binding site and increasing the intrinsic effect of endogenous glutamate, 
leading to the enhancement of NMDA receptor function.  It was also hypothesized that 
fish treated with both MK-801 and CHPG would exhibit significantly lower motor 
activity than the group treated with MK-801 alone, and would not differ significantly 
from the control group or the group treated with CHPG alone.  This prediction was based 
on observations from rodent studies that indicated an ability of CHPG to reverse NMDA-
R antagonist-induced motor effects, while not having an independent effect on 
spontaneous motor activity.    
1.1 Subjects 
 Fertilized zebrafish eggs were obtained from Z-FIN Lab in Orgeon, and housed 
on Bard College campus on a 14-hour lights on/off cycle.  Zebrafish larvae were tested at 
5 d.p.f. (days post-fertilization).   
1.2 Materials 
 MK-801 was obtained from Research Biochemicals International (Natick, MA).  
CHPG was obtained from Tocris Bioscience, Inc.  CHPG sodium salt was used based on 
optimal water solubility.  6.7 mg MK-801 was dissolved in 10 mL egg water to yield a 
stock solution of 2000 µM MK-801; the stock was then diluted to yield 30 mL solution of 
20 µM MK-801.  5 mg CHPG was dissolved in 60 mL egg water to yield a stock solution 
of 360 µM CHPG, which was then diluted with egg water to yield a solution of a solution 
of 180 µM CHPG.  Stock solution of MK-801 and CHPG were diluted to yield a single 
solution of 20 µM MK-801 and 180 µM CHPG.   
 Zebrafish behavior was observed using a mounted Ikegami camera over 8 well 
plates on a 24 well plate dish, and recorded with Noldus EthoVisionXT at an applied 
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sampling rate of 29.97 samples/second.  Detection settings were set as follows: Dynamic 
Subtraction; frame weight: 20; dark contrast: 19-134; subject size minimum: 8 pixels, 
subject size maximum: 1519 pixels.  Data output was exported into Microsoft Excel and 
then transferred into SPSS.  All data analyses were conducted using SPSS.   
1.3  Procedure 
 Zebrafish were observed in round well plates each 2 cm in diameter.  8 fish were 
observed at a time, with a total of 104 fish.  First, 1 mL egg water was added into each 
individual well.  Zebrafish were transferred into each well by a pipette.  Baseline activity 
was recorded for 5 minutes.  The egg water was removed from the wells, leaving just 
enough for the larvae to swim in the perimeter. During the test period subjects received 
either: a) 1 mL of egg water (control group; n = 26); b) 1 mL containing 20 µM MK-801 
(n = 26); c) 1 mL containing 180 µM CHPG (n = 26); or d) 1 mL containing 20 µM MK-
801 and 180 µM CHPG (n = 26). We did not counter-balance the location of treatment 
administration in the well plates, because based on past experience the location of 
treatment administration would not be expected to affect the results.  Motor activity was 
recorded for 15 minutes during the test period.  After testing, zebrafish were left in the 
well plates for the rest of the day and observed for lethal effects of CHPG and MK-801. 
1.4 Measures 
 Fourteen movement parameters were recorded and analyzed.  These were as 
follows: Total distance traveled (millimeters); duration of movement in zone B (seconds); 
frequency of movement in zone B; latency to first move in zone B (seconds); duration of 
movement in zone C (seconds); frequency of movement in zone C; latency to first move 
in zone C (seconds); duration of movement overall (seconds); frequency of movement; 
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latency to first move (seconds); duration of immobility overall (seconds); frequency of 
not moving; latency to first stop moving (seconds); mean velocity (millimeters/seconds).  
1.5 Data Analysis 
 The analysis output was exported from EthoVision as a Microsoft Excel file.  
Data was analyzed in a one-way ANOVA with condition (1 = control, 2 = MK-801, 3 = 
CHPG, 4 = MK-801 + CHPG) as the independent variable.  A separate one-way ANOVA 
was conducted to determine if baseline differences in activity existed.  One-way ANOVA 
tests were performed separately for each of the dependent measures described in 1.4.  
Tukey post-hoc tests were performed in order to make specific group expansions.  All 
significance levels were set at p < 0.05. 
1.6 Results 
 ANOVA tests conducted for all dependent variables at baseline showed that no 
significant differences existed between groups prior to drug administration.  Although 
there was a trend for groups 3 and 4 (CHPG and MK-801/CHPG, respectively) to be less 
active at baseline, there were no significant differences detected.  Tables 1 and 2 display 
the mean distance traveled for each group during baseline and test recordings.   
Table 1. Pre-Treatment Mean Distance Traveled (5 minutes) 
 
 
Condition 
 
N Mean Total 
Distance Traveled 
(mm) 
ANOVA Statstics 
Control 23 390.9 ± 37. 7 F (3, 96) = 1.422 
MK801 26 344.2 ± 43.5 p = .241 
CHPG 26 287.1 ± 38.5  
MK801+CHPG 25 290.9 ± 41. 4  
Total 100 326.8 ± 20.4  
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Table 2. Post-Treatment Mean Distance Traveled (15 minutes) 
Condition N Mean Total 
Distance Traveled 
(mm) 
ANOVA Statistics 
Control 26 1232.4 ± 122.2 F (3, 98) = 9.735 
MK801 26 797.8 ± 90.0 p < .001 
CHPG 25 1377.5 ± 87.5  
MK801+CHPG 25 766.1 ± 87.6  
Total 102 1042.9 ± 55.2  
 
  Table 1 shows that there were no pre-treatment differences in the total distance 
traveled by the larvae.  Table 2 shows that there was a significant difference between 
groups after treatment.  ANOVA tests conducted for all dependent variables at baseline 
showed that no significant differences existed between groups prior to drug 
administration.  The results of a one-way ANOVA indicated the groups differed 
significantly on total distance moved, F (3, 98) = 9.735, p < .001.  Post-hoc analysis 
indicated that Group 1 (control) and Group 3 (CHPG alone) were more active than Group 
2 (MK-801) and Group 4 (MK-801 + CHPG).  A Tukey HSD test indicated that controls 
traveled a greater mean total distance than larvae treated with MK-801 (mean difference 
= 434.6, p = .011) and larvae treated with MK-801/CHPG (MD = 466.3, p = .006); larvae 
treated with CHPG alone traveled a greater mean distance than larvae treated with MK-
801 (MD = 579.6, p < .001) and larvae treated with MK-801/CHPG (MD = 611.3, p < 
.001).   
 Control 20 µM MK-801 180 µM CHPG MK-801 + 
CHPG 
Total distance 
traveled (mm) 
(Mean± 
S.E.M.)  
1232.4 ± 122.2 
+ ^ 
797.8 ± 90.0     
* # 
1377.5 ± 87.5 
+ ^     
766.1 ± 87.6 
* # 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
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Figure 1. Larvae receiving MK-801 or co-administration of MK-801/CHPG traveled 
significantly less than controls or larvae treated with CHPG alone (F (3, 98) = 9.735, p < 
.001).  Pre- and post-treatment data are shown.   
 
This particular result was unexpected because it was hypothesized that larvae treated with 
MK-801 would travel greater distance than controls, and that larvae treated with MK-
801/CHPG would not differ from controls.  However, as is shown below, the larvae in 
those both of those groups were less active than controls on several activity parameters.  
Controls and larvae treated with CHPG alone entered the perimeter (zone B) of the well 
more frequently than larvae treated with MK-801 or MK-801/CHPG (F (3,100) = 7.631, 
p < .001), while not differing significantly from each other.  A post-hoc Tukey HSD test 
indicated that controls differed from larvae treated with MK-801 (MD = 60.2, p < .008) 
and from larvae treated with MK-801/CHPG (MD = 65.3, p = .003). Larvae treated with 
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CHPG alone entered the perimeter significantly more than larvae treated with MK-801 
(MD = 59.3, p = .009) and larvae treated with MK-801/CHPG (MD = 64.3, p = .004). 
 Control MK-801 CHPG MK-801 + 
CHPG 
Zone B 
frequency  
110.1 ± 17.6 
+ ^ 
49.8 ± 8.6 
* # 
109.1 ± 15.3 
+ ^ 
44.8 ± 7.5 
* # 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
 
In addition to the result that larvae treated with MK-801 or MK-801/CHPG entered the 
perimeter less frequently than controls, a one-way ANOVA indicated a significant 
between groups difference on frequency of entering the center of the well that followed a 
similar trend (F (3, 100) = 7.448, p < .001).  Tukey post-hoc analysis indicated that 
controls entered more frequently than larvae treated with MK-801 (MD = 59.96, p = 
.007) and larvae treated with MK-801/CHPG (MD = 63.57, p = .004); larvae treated with 
CHPG alone entered the center more frequently than larvae treated with MK-801 (MD = 
57.73, p = .010) and larvae treated with MK-801/CHPG (MD = 61.34, p .006).  Taken 
together, these two results suggest that larvae treated with MK-801 moved less overall 
than controls.   
 Control MK-801 CHPG MK-801 + 
CHPG 
Zone C 
frequency 
108.0 ± 17.6 
+ ^ 
48.08 ± 8.5 
* # 
105.8 ± 14.7 
+ ^ 
44.4 ± 7.5 
* # 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
 
This was confirmed by results indicating a significant between groups difference for 
movement duration (F (3, 98) = 4.007, p = .010).  A post-hoc Tukey test indicated that 
larvae treated with MK-801 moved for a shorter amount of time than controls (MD = -
ASSESSMENT OF A NOVEL ANTIPSYCHOTIC IN ZEBRAFISH 44 
134.1, p = .027) and larvae treated with CHPG alone (MD = -131.39, p = .034); the other 
three groups did not differ significantly from each other.  
   
 Control MK-801 CHPG MK-801 + 
CHPG 
Movement 
duration (s) 
694.8 ± 28.2 
+ 
560.7 ± 37.7 
* # 
692.1 ± 22.7 
+ 
601.3 ± 42.1 
 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
 
In addition to the difference in movement duration, there was significant difference 
between groups for movement frequency (F (3, 100) = 6.905, p < .001), and a post-hoc 
Tukey test indicated that larvae treated with MK-801 moved less frequently than larvae 
treated with CHPG (MD = -71.65, p = .002), and larvae treated with CHPG alone moved 
more frequently than larvae treated with MK-801/CHPG (MD = 70.6, p = .002). 
 Control  MK-801 CHPG MK-801 + 
CHPG 
Movement 
frequency 
139.7 ± 15.3 
 
89.6 ± 12.6 
# 
161.27 ± 13.7 
+ ^ 
90.5 ± 12.7 
# 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
 
Given that the groups differed on duration of mobility, it would be expected that they 
would also differ on duration of immobility.  This was confirmed by results indicating 
that there was a significant between groups difference for duration of time spent 
immobile (F (3, 96) = 6.384, p = .001), and a post-hoc Tukey test indicated that larvae 
treated with MK-801 spent less time moving than controls (MD = 133.3, p = .015) and 
larvae treated with CHPG alone (MD = 157.95, p = .003); larvae treated with MK-
801/CHPG spent less time moving than larvae treated with CHPG alone (MD = 134, p = 
.017) but did not spend significantly less time moving than controls (p = .073). 
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 Control MK-801 CHPG MK-801 + 
CHPG 
Not moving 
duration (s) 
202.3 ± 26.6 
+ 
 
335.7 ± 35.5 
* # 
177.7 ± 14.9 
+ ^ 
311.7 ± 41.4 
# 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
 
A one-way ANOVA indicated a significant difference between groups for not moving 
frequency (F (3, 100) = 6.891, p < .001), as would be expected from the results indicating 
a difference between frequency of movement in each group.  A post-hoc Tukey test 
indicated that larvae treated with CHPG alone were more frequently immobile than 
larvae treated with MK-801 (MD = 71.6, p = .002) and larvae treated with MK-
801/CHPG (MD = 70.5, p = .002).  These results are consistent with the earlier results 
indicating significant differences in movement frequency.   
 Control MK-801 CHPG MK-801 + 
CHPG 
Not moving 
frequency 
139.4 ± 15.3 
 
89.1 ± 12.7 
# 
160.8 ± 13.7 
+ ^ 
90.27 ± 12.7 
# 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
 
F scores for Experiment 1 are reported below in Table 3. 
Table 3. F Statistics for Dependent Variables in Experiment 1 
 
Dependent Variable F score p value 
Total distance moved 9.735 <.001* 
Zone B duration  .992 .400 
Zone B frequency 7.631 <.001* 
Zone B latency to enter 1.862 .141 
Zone C duration  2.425 .071 
Zone C frequency 7.448 <.001* 
Zone C latency to enter .950 .420 
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Movement duration 4.007 .010* 
Movement frequency 6.905 <.001* 
Latency to first move 1.479 .225 
Not moving duration 6.384 .001* 
Not moving frequency 6.891 <.001* 
Latency to first stop moving .925 .432 
Mean velocity 2.132 .101 
 
In summary, fish treated with either 20 µM MK-801 or 20µ MK-801/180 µM CHPG 
tended to be more active than controls on total distance moved, frequency of entering the 
perimeter of the well, frequency of entering the center of the well, movement duration, 
and movement frequency, while fish treated with CHPG alone tended not to differ from 
controls on any movement parameters. 
 
Experiment 2 
 The results of the first experiment prompted us to modify the dosage of both MK-
801 and CHPG in Experiment 2.  It was hypothesized that lowering the dose of MK-801 
to 2 µM could effect motor behavior in the larvae that would be more consistent with 
previous literature demonstrating that MK-801 can induce hyperactivity in zebrafish.  It 
was thought that the dose of 20 µM may have been extremely high for the larvae and thus 
reduced motor activity, so a lower dose was investigated.  Furthermore, because CHPG 
did not appear to have an effect at the dose of 180 µM it was hypothesized that a higher 
dose would be necessary in order to significantly reduce the motor effects of MK-801, 
and therefore in the second experiment larvae received a dose of 360 µM CHPG.  Aside 
from dose levels the procedure was not modified because the data suggested that 
significant differences were due to drug effects, rather than an effect of the procedure 
itself.   
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2.1 Procedure 
 In the second experiment  a lower dose (2 µM) of MK-801 was used and a higher 
dose (360 µM) of CHPG was used. During the test period subjects received either: a) 1 
mL of egg water (control group; n = 26); b) 1 mL containing 2 µM MK-801 (n = 26); c) 1 
mL containing 360 µM CHPG (n = 26); or d) 1 mL containing 2 µM MK-801 and 360 
µM CHPG (n = 26).  The same procedure that was used in Experiment 1 was used in 
Experiment 2.   The measures that were recorded were the same in both experiments.  
Baseline activity was also compared across both experiments to determine if there were 
differences between the subjects on the two separate days.  One minor change in the 
second experiment was a reduction in ambient light, which necessitated systematically 
turning the lights on and off during the procedure.  
2.2 Results 
 Baseline activity was analyzed by a one-way ANOVA and the results and 
indicated no significant differences between groups prior to drug administration.  One-
way ANOVA tests indicated significant differences between groups on several measures 
of activity after drug administration.  The results were surprising in that they indicated an 
independent effect of CHPG on locomotor activity that was unexpected.  In general, 
larvae treated with CHPG alone were more active than larvae receiving other treatments 
or controls.  
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 Controls 2 µM MK-801 360 µM CHPG MK-801 + 
CHPG 
Total distance 
traveled (mm) 
(Mean ± 
S.E.M.) 
2371.2 ± 156.3 
# 
2540.4 ± 206.0 
 
3112.6 ± 161.2 
* ^ 
2349.1 ± 136.3 
# 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
 
Figure 2.  Larvae treated with CHPG traveled significantly greater distance than controls. 
  
Groups differed on total distance traveled (F (3, 100) = 4.562, p = .005); a Tukey post-
hoc test indicated that larvae treated with 360 µM CHPG traveled greater total distance  
than controls (MD = 741.4, p = .012) and larvae treated with MK-801/CHPG (MD = 
763.5, p = .009), but not larvae treated with 2 µM MK-801 (MD = 572.1, p = .079).  
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Figure 3. Tracks from Trial 18.  From left to right, each column of two represents the different groups: 
controls. MK-801, CHPG, MK-801 + CHPG.  Above is the plotted tracks of movement over the 15 minute 
test period, representing the total distance moved. 
 
A one-way ANOVA indicated that groups differed significantly on duration of time spent 
in zone B (F (3, 99) = 3.116, p = .030); a Tukey post-hoc test indicated that larvae treated 
with 2 µM MK-801 spent more time in zone B than larvae treated with MK-801 and 
CHPG (MD = 117.03, p = .046).  It is not clear exactly what this result indicates.   
 Controls MK-801 CHPG MK-801 + 
CHPG 
Zone B 
duration (s) 
672.1 ± 28.4 
 
687.7 ± 33.3 
^ 
681.3 ± 24.9 
 
570.7 ± 37.1 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
 
 
Similarly, differences in latency to enter the center of the well seem ambiguous as to their 
meaning.  Analysis with a one-way ANOVA test indicated that there was a significant 
between groups difference in latency to enter zone C (F (3, 99) = 3.293, p = .024); a 
Tukey post-hoc test indicated that the larvae receiving MK-801/CHPG took significant 
longer to enter zone C than controls (MD = 58.7, p = .044). 
 Controls MK-801 CHPG MK-801 + 
CHPG 
Zone C latency 
to enter (s) 
4.1 ± 1.4 
^ 
5.2 ± 1.4 
 
9.7 ± 6.0 62.8 ± 30.4 
* 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
QuickTime™ and a
 decompressor
are needed to see this picture.
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A one-way ANOVA test indicated significant between groups differences on movement 
duration (F (3, 100) = 3.320, p = .023); a Tukey post-hoc test indicated that larvae 
receiving 360 µM CHPG moved for longer than the control group (MD = 129.1, p = 
.033).   
 Controls MK-801 CHPG MK-801 + 
CHPG 
Movement 
duration (s) 
586.3 ± 38.5 
# 
595.2 ± 40.8 
 
715.5 ± 25.1 
* 
608.5 ± 23.7 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
 
 
These results are consistent with the findings of a one-way ANOVA that indicated a 
significant between groups difference on duration of not moving (F (3, 100) = 3.335, p 
=.022); a Tukey post-hoc test indicated that the larvae treated with CHPG alone spent 
significantly less time immobile than controls (MD = -129.1, p = .033), and there was a 
marginally significant difference between the larvae treated with CHPG and larvae 
treated with 2 µM MK-801 (MD = -120.3, p = .054).  
 
 Controls MK-801 CHPG MK-801 + 
CHPG 
Not moving 
duration (s) 
314.6 ± 38.4 
# 
305.7 ± 40.8 
 
185.4 ± 25.1 
* 
292.4 ± 23.6 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
 
Analysis by one-way ANOVA indicated a significant between groups difference on 
latency to first stop moving (F (3, 100) = 4.579, p = .005); a Tukey post-hoc test 
indicated that larvae treated with 2 µM MK-801 were quicker to first stop moving than 
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larvae treated with MK-801/CHPG (MD = -16.4, p = .019), and larvae treated with MK-
801/CHPG took significantly longer to first stop moving than controls (MD = 16.7, p = 
.016) and larvae treated with CHPG alone (MD = 17.04, p = .014).  It is interesting to 
note here that the standard error of the mean is significantly higher for the MK-
801/CHPG group and this could explaining the discrepancy.   
 Controls MK-801 CHPG MK-801 + 
CHPG 
Not moving 
latency (s) 
2.4 ± 0.7 
^ 
2.7 ± 0.5 
^ 
2.1 ± 0.4 
^ 
19.2 ± 7.7 
* + # 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
 
Lastly, a one-way ANOVA indicated a significant between groups difference on mean 
velocity (F (3, 100) = 4.059, p = .009); a post-hoc Tukey test indicated that larvae treated 
with 360 µM CHPG had higher mean velocity than controls (MD = .793 mm/s, p = .015) 
and larvae treated with MK-801/CHPG (MD = .756, p = .023).  Taken along with the 
results indicating larvae receiving CHPG moved for longer than other larvae, the higher 
average velocity of these larvae is consistent with the results indicating that this group 
traveled a greater total distance than controls.    
 Controls MK-801 CHPG MK-801 + 
CHPG 
Mean velocity 
(mm/s) 
2.6 ± 0.1 
# 
2.8 ± 0.2 
 
3.4 ± 0.1 
* ^ 
2.7 ± 0.1 
# 
*different than controls; + different than MK-801; # different than CHPG; ^ different than MK-
801 and CHPG 
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All F scores for Experiment 2 are reported below in Table 4. 
Table 4.  F Statistics for Dependent Variables in Experiment 2. 
Dependent Variable F Score p Value 
Total distance traveled 4.562 .005* 
Zone B duration 3.116 .030* 
Zone B frequency 1.343 .265 
Zone B latency to enter .364 .779 
Zone C duration 2.391 .073 
Zone C frequency  1.366 .257 
Zone C latency to enter 3.293 .024* 
Movement duration 3.320 .023* 
Movement frequency .504 .680 
Latency to first move .301 .825 
Not moving duration 3.335 .022* 
Not moving frequency .511 .676 
Latency to first stop moving 4.579 .005* 
Mean velocity 4.059 .009* 
 
In summary, larvae treated with CHPG alone tended to be more active than controls 
(traveling greater total distance, moving for longer duration, and moving with a greater 
velocity), while larvae receiving MK-801 or MK-801/CHPG generally did not exhibit 
different motor behavior than controls.  
 
Discussion 
 Previous research has demonstrated that adult zebrafish treated with MK-801 
exhibit increased motor activity (Swain et. al. 2004; Seibt et. al. 2010; Seibt et. al. 2011), 
consistent with the effects of NMDA-R antagonism in other rodent models.  The findings 
of Chen et. al. (2010) demonstrated that these effects are conserved in larval zebrafish.  
Based on these findings, administration of MK-801 was expected to increase larval 
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zebrafish motor activity in our first experiment.  However, this was not observed in 
Experiment 1.  Rather, the zebrafish larvae treated with MK-801 or the combination of 
MK-801 and CHPG showed significantly decreased motor activity compared to controls 
and larvae treated with CHPG alone.  Larvae treated with MK-801 traveled less total 
distance than controls and larvae treated with.  Furthermore, analyses of several of the 
dependent variables from both experiments indicate a trend for larvae treated with MK-
801 and MK-801/CHPG to be less active than controls or larvae treated with CHPG 
alone.  The results of Experiment 1 were part of the rationale for changing the dose levels 
in Experiment 2.  It was considered a possibility that at the dose level of 20 µM, MK-801 
was acting as an anesthetic and thereby impairing the larvae’s ability to move normally.  
Indeed, very high doses of MK-801 have also been shown to impair the control of motor 
movement in rats, and it is a possibility that the decreased motor activity seen in 
Experiment 1 is representative of a disruption of the larvae’s ability to control their 
swimming motions (Kovacic & Somanathan 2010).  Therefore, we hypothesized that 
administering a smaller dose of MK-801 would be more likely to elicit an increase in 
motor activity that would be more consistent with the current literature.    
 Contrary to this hypothesis, MK-801 did not affect larval motor activity at the 
dose level of 2 µM in Experiment 2.  In fact, there were no significant differences 
between controls and larvae treated with 2 µM MK-801, suggesting that at this dose level 
MK-801 does not have an effect on motor activity in zebrafish larvae.  However, it is 
interesting to note that results seemed to indicate an interaction between MK-801 and 
CHPG at this dose level.  Larvae treated with 360 µM CHPG were more active than 
controls on several parameters, but larvae who received MK-801 and CHPG co-
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administration frequently did not differ from controls on the same parameters.  This 
suggests that although MK-801 was not behaviorally active by itself at the 2 µM dose 
level, some drug interaction between MK-801 and CHPG did prevent an overall motor 
activity increase such as was seen in the larvae that received CHPG alone.     
 CHPG was not expected to have any effects on motor activity when administered 
alone, as Kinney et al. (2003) and Chan et. al. (2008) demonstrated that CHPG does not 
alter motor activity in rodents when administered alone, despite reversing motor effects 
of NMDA-R antagonism in these models.  While the data from Experiment 1 supports 
the hypothesis that CHPG by itself will not affect motor activity, the data from 
Experiment 2 indicated increased activity on several motor parameters at a dose of 360 
µM.  At this dose level, CHPG administration led to an increase in (1) total distance 
traveled, (2) duration of movement, and (3) mean velocity, as well as a decrease in the 
duration of time spent immobile, in comparison to controls.  This is contrary to the 
expectation that activation of mGluR5 would not affect motor behavior on its own due to 
the proposed mechanisms by which mGluR5 enhances NMDA-R function. According to 
Kanuma et. al. (2010) the mechanism by which activation of mGluR5 with agonist agents 
enhances NMDAR function is that it is likely that activation of mGluR5 leads to PKC 
phosphorylation of the ion channel associated with NMDA receptors, thereby resulting in 
increased NMDA receptor sensitivity and activity, and leading to an influx of calcium 
ions.  However, this hypothesis comes out of findings from rodent studies, and it may not 
be possible to extrapolate this proposed mechanism to a zebrafish model.  In the zebrafish 
brain the mGluR5 may have the ability to more directly affect glutamatergic transmission 
in neuronal circuits governing motor activity, and thus CHPG-induced activity at the 
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receptor leads to increased motor activity.  Future research could investigate whether 
administration of a high dose of another mGluR5 agonist causes the same increase in 
motor activity, as well as whether inhibition of the receptor via mGluR5 agonism can 
lead to a decrease in motor activity at any dose level.  The findings of the present study 
may suggest that in the central nervous system of the larval zebrafish mGluR5 may be 
more directly linked to neuronal systems governing motor activity than in the rodent or 
human nervous system.  The data indicated that at 5 dpf the larval nervous system is 
sufficiently developed for mGluR5 agonism to have an effect on behavior.  Further 
investigation into the nature of this connection could lead to a more comprehensive and 
refined understanding of the glutamatergic systems in zebrafish and their relationship to 
motor behavior.  It should be noted that there is also always the possibility that CHPG 
increased motor activity by some means other than mGluR5 agonism.  The ontogeny 
(development) of mGluR5 does not appear to be available in the literature regarding 
mGluR5 orthologs yet.  The data evidences that CHPG is behaviorally active in zebrafish 
larvae at 5 d.p.f..  If the mGluR5 is not expressed by 5 dpf, it would appear that CHPG is 
acting on different systems than previously thought. 
 With regard to potential toxicity of MK-801 and CHPG, during both experiments 
well plates were kept in another room of the lab after treatment and observation, in order 
for us to assess any lethal toxicity of both drugs.  None of the fish died at either dose 
administered.  This indicates that at this dose range, lengthy exposure to either MK-801 
or CHPG is not lethal to zebrafish larvae at these dose levels.  
 The data from experiments do not support an ability of CHPG to reverse the 
effects of MK-801 at a dose of either 180 µM or 360 µM.  A lack of significant 
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differences between the controls and the larvae treated with MK-801/CHPG (on 
dependent variables where larvae treated with MK-801 alone differed from control) 
would suggest that CHPG was reversing the motor effects of CHPG. In Experiment 1, the 
group receiving MK-801 and CHPG did not move for a significantly different amount of 
time than the controls or the group receiving CHPG alone.  However, both groups that 
received MK-801 traveled for significantly less distance than the groups that did not 
receive MK-801.  There seems to be the possibility that in the group that received a co-
administration of both drugs, CHPG was able to rescue the subjects from increased 
immobility due to MK-801 administration.  This tendency to spend more time immobile 
than controls may indicate a disruption by NMDA-R antagonism that is reversible by 
CHPG.  However, it would be premature to make this conclusion in the absence of other 
results supporting CHPG's ability to reverse MK-801 effects.  It is likely that this effect 
of CHPG on movement duration is caused via the same mechanism by which a higher 
dose of CHPG increased motor activity in the second experiment.  Though what exactly 
this mechanism is remains for the moment unknown, the results of this study do suggest a 
dose-dependent effect of CHPG on motor activity.  
 It should also be considered that CHPG may not be potent enough to have 
reversed the effects of the high dose of MK-801 in Experiment 1 on the majority of 
movement parameters.  Recent literature reviews have cited lower relative potency of 
some mGluR5 agonists as a rationale for the development of positive allosteric 
modulators (PAMs) of mGluR5, such as the compounds CDPPB and ADX47273 
(Kanuma et. al. 2010; Niswender and Conn 2010).  Given that CHPG did not 
demonstrate a rescue effect at a dose of 180 µM, while at a dose of 360 µM increased 
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motor activity when administered alone, the data of the present study may indicate that 
such a high dose of CHPG is needed to have an antipsychotic effect that there is a risk of 
increased motor side effects.  In the context of the development of new antipsychotics, 
the implication is that positive allosteric modulation is most likely a more desirable 
pharmacotherapy to investigate for the treatment of schizophrenic symptoms.  Future 
research could assess whether administration of an mGluR5 PAM would lead to similar 
behavioral results as the dose of 360 µM CHPG.  
 It was hypothesized that in Experiment 1 the differences between the group 
receiving MK-801/CHPG and the controls would not be statistically significant.  
However, most of the differences between controls and larvae co-treated with 2 µM MK-
801/360 µM CHPG were indeed significant.  The only non-significant differences were 
(1) a Tukey post-hoc test indicated no significant difference from controls for movement 
duration and movement frequency, and (2) a Tukey post-hoc test on duration and 
frequency of immobility indicated no significant differences from controls.  The findings 
the first experiment suggested that a higher dose of CHPG was needed to reverse motor 
effects of MK-801, providing the rationale for investigating the dose level of 360 µM in 
Experiment 2.  In the second experiment, larvae co-treated with 2 µM MK-801 and 360 
µM CHPG did not differ significantly from the control group except on: (1) duration of 
time in zone B, (2) latency to enter zone C, (3) latency to first stop moving.  Given that 
overall the larvae treated with 360 µM exhibited locomotor hyperactivity on several 
measures, it would seem that the 2 µM dose of MK-801 is preventing the increases in 
motor activity induced by CHPG administration, while by and large having no effect on 
motor activity when administered alone. 
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 These results are surprising, but one plausible explanation is that the 2 µM dose of 
MK-801 could have decreased activity level by such a small amount that it was not 
statistically significant by itself, but was enough to prevent the motor effects that were 
seen when CHPG was administered alone.  One factor that could have contributed to this 
effect is the fact that the drugs were administered simultaneously.  It could be the case 
that the simultaneous blockade of the NMDA-R by MK-801 prevented CHPG from 
affecting motor behavior.  CHPG has been proposed to modulate transmission at the 
NMDA receptor, but if MK-801 was already preventing glutamatergic transmission it 
would make sense that CHPG was unable to modulate motor activity by this proposed 
mechanism.   Further research could explore the mechanism by which this effect is 
caused, but it would seem that currently not enough is known about metabotropic 
modulation of the glutamatergic systems in the zebrafish CNS to come to a clear and 
compelling conclusion for why the larvae that received co-treatment did not differ from 
controls on the measures that larvae treated with CHPG did.   
 While the data does not largely suggest the presence of confounding variables, the 
possibility should never be ignored.  Importantly, it should be noted that the subjects in 
the two experiments differed on several parameters of baseline activity.  The subjects in 
Experiment 2 tended to be more active overall than the subjects in Experiment 1.  For 
instance, though the movement duration of the subjects in both experiments did not differ 
in a statistically significant manner, subjects in Experiment 2 moved roughly 2.5 times 
greater total distance than subjects in Experiment 1.  This suggests that the subjects in 
Experiment 2 moved at a higher mean velocity, which is confirmed by the data (t = -
3.298, df = 202, p < .001).  This increased activity could be an effect of differences in 
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light level between the two experiments : during the first experiment, we did not cover 
the window when we began running subjects.  After a few hours of testing ambient light 
levels increased due to sunlight coming in the window.  A majority of light was blocked 
for the remaining trials.  In contrast, when we ran the second experiment the window was 
covered the entire time.  However, because the low light level made handling the larvae 
and drug administration difficult, the following procedure was followed: 1) When placing 
fish in wells, lights were turned on; 2) before recording 5 minutes of baseline activity, 
lights were turned off; 3) before administering the drug treatments, lights were turned on; 
4) before recording 15 minutes of post-treatment activity, lights were turned off.  There 
has been a noted effect of light transitions on motor activity in zebrafish.  Padilla et. al. 
(2011) demonstrated that both level of light and and the order of light presentation can 
influence motor activity in larval zebrafish 6 d.p.f..  It is unfortunate that these baseline 
differences exist because they suggest possible extraneous variables affecting the data.  
However, in neither experiment were there significant differences between groups during 
baseline activity, suggesting that the observed drug effects can be considered valid.  
 Another important factor that should be mentioned is that the zebrafish larvae 
used in both studies were wild-type (tupel long fin) TL zebrafish, a strain that has not 
been used before in assessing the behavioral effects of MK-801 administration.  Chen et. 
al. (2010) reported conservation of MK-801 motor effects in zebrafish larvae, but those 
were a wild-type AB strain.  It may be that the TL strain is more sensitive to MK-801 
treatment, and therefore the dose level of 20 µM may have had an effect that is only seen 
at much higher dose levels in other strains of zebrafish.  It may also be the case that there 
are developmental differences in the glutamate systems between the two strains: Chen et. 
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al. found that MK-801 was not behaviorally active in the AB larvae until 5 d.p.f..  It may 
be that there exist subtle developmental differences at 5 d.p.f. between AB and TL larvae 
which could account in part for the discrepancy between the results of Chen et. al.’s study 
and the results of the present study.  Additionally, it could be the case that the exposure 
time (15 min) was not long enough to elicit the expected increase in motor activity in 
either experiment.  Because our 20 µM dose elicited a decrease in motor activity, but our 
2 µM dose did not elicit any significant response, it would be interesting to conduct 
further research to assess how larval TL zebrafish respond to doses in between 2-20 µM.  
Lastly, there is always the possibility that having a different commercial source than that 
of the research previously cited impacted MK-801 responsiveness.  Further research 
should investigate at what dose, if any, MK-801 can elicit increased motor activity in TL 
larvae. 
 In summary, although the current study failed to demonstrate an increase in motor 
activity following treatment with MK-801, we did demonstrate behavioral effects of a 
novel mGluR5 agonist, CHPG, at a dose of 360 µM.  These effects were generally 
inhibited by co-administration of 2 µM MK-801.  Furthermore, the results of the current 
study are consistent with the findings of Padilla et. al. (2011) which indicate that light-to-
dark transitions can influence motor activity in zebrafish larvae as early as 5 dpf.  The 
present data support further investigation into how the glutamate systems in the larval 
zebrafish brain effect motor behavior. 
 
ASSESSMENT OF A NOVEL ANTIPSYCHOTIC IN ZEBRAFISH 61 
 
Chapter 5: Conclusion 
 The emergence of the glutamate hypothesis of schizophrenia represents an 
important shift in focus away from dopaminergic systems and onto glutamatergic 
transmission at the NMDA receptor.  Dissociative anestheticsthat antagonize the NMDA 
receptor, such as MK-801, have begun to be utilized as psychotomimetics due to their 
ability to induce deficits that more accurately resemble the symptoms of the disorder.  
Several agents that enhance NMDA-R function via activation of metabotropic glutamate 
receptors have been developed and are currently being explored as alternative approaches 
to antipsychotic drug therapy.     
 The use of animal models is an essential part of the process of understanding and 
developing the pharmacological profile of novel antipsychotics.  MK-801’s ability to 
schizophrenic-like behavior in rodent and zebrafish models makes a full assessment of its 
behavioral effects important and relevant to current progress towards improved treatment 
models.  The assessment of the behavioral effects of MK-801 in animal models is 
relevant to the development of novel antipsychotic drugs based on the glutamate 
hypothesis.  The purpose of the study conducted in this senior project was to determine 
whether zebrafish larvae could serve as a model to investigate the antipsychotic effects of 
CHPG, a novel metabotropic glutamate receptor 5 selective agonist.  The principle 
questions of interest were: a) can treatment with MK-801 disrupt motor activity in 
zebrafish larvae in a manner consistent with the current scientific literature?; b) what, if 
any, are the motor effects induced by treatment with CHPG by itself?; and c) can co-
administration of CHPG with MK-801 rescue larvae from MK-801-induced motor 
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disturbances?  While in the second experiment the co-administration of CHPG and MK-
801 did not result in any significant differences in motor activity from controls, it is 
unclear by what mechanism these results is were demonstrated.  The motor effects of the 
highest dose of CHPG could be indicative that in the larval zebrafish mGluR5 agonism 
affects behavior in a different and perhaps more direct way than in previously explored 
rodent models.  Furthermore, the present findings support the findings of Chen et. al. 
(2010) that at a dose of 20 µM MK-801 can disrupt behavior in zebrafish larvae, but 
whereas Chen et. al. found an increase in motor activity, we consistently found a decrease 
in motor activity at this dose level.  These findings suggest that further research ought to 
be conducted regarding the character of larval zebrafish’s behavioral response to MK-801 
administration.  Further investigation of the mechanisms underlying the reasons that the 
larvae responded the way they did to MK-801 administration could help provide a more 
comprehensive model for NMDA-R mediated behavior in zebrafish.  Additionally, 
further research into dose-dependent responses to mGluR5 agonism could help to 
illuminate how this particular receptor affects motor behavior in zebrafish. 
 Because this particular area of research is a growing one, easy explanations for 
the results of the present study are not yet readily available in the literature.  Therefore, 
what this senior project seeks to contribute is several questions for possible empirical 
studies in the future:  Are the motor effects of 20 µM MK-801 confined to TL larvae, or 
can these findings be replicated in other strains such as AB larvae?  At what dose levels, 
if any, will MK-801 increase spontaneous motor activity in TL larvae (5 dpf) in a way 
that is consistent with the existing literature?   For instance, what would be the results of 
treatment with a dose of MK-801 in between the two dose levels (2 µM and 20 µM)  
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administered in the present study?  What would be the motor effects of longer exposure 
time –  for instance 30, 60, or 90 minutes?  Are the motor effects of a 20 µM dose of 
MK-801 different in TL larvae at 6 dpf and 7 dpf than at 5 dpf?  Additionally, what are 
the independent motor effects of CHPG in zebrafish larvae at doses that fall in between 
the range of 180-360 µM?  Can CHPG reverse MK-801-induced motor disturbances if 
larvae are pre-treated with it?  Does a 360 µM dose of CHPG increase motor activity in 
larvae at 6 dpf or 7 dpf?  Research that seeks to address these question will serve to 
clarify the use of zebrafish larvae as a model of NMDA-R mediated psychosis by 
providing a more sophisticated picture of how glutamate systems affect behavior in this 
model.  
 The rising popularity of the zebrafish as a model organism for CNS disorders has 
come at the same time as the developers of antipsychotic agents have shifted their focus 
onto ligands that enhance glutamatergic transmission at the NMDA-R receptor. It has 
been hypothesized that glutamatergic modulation presents a more comprehensive strategy 
for ameliorating schizophrenic symptoms while causing less side effects than 
conventionally prescribed antipsychotics.  A clearer understanding of the way that 
glutamate transmission effects behavior in the larval zebrafish will inform researchers as 
to whether or not the larval zebrafish can be a useful model to investigate the 
antipsychotic efficacy of many of these new agents.  If larval zebrafish can indeed serve 
as a model, it represents a cost-effective and efficient way to evaluate the efficacy of new 
antipsychotics which may have far-reaching effects in combating the personal and social 
costs of schizophrenia. 
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